GLP-1 and Snoring: The Sleep Apnea Data Men Should See

If you snore, there's roughly a 1 in 4 chance you have obstructive sleep apnea. If you're a man with obesity who snores, that probability climbs significantly higher. Sleep apnea affects an estimated 24% of men versus 9% of women, and about 60-70% of OSA patients have obesity as a contributing factor.

The standard treatment — a CPAP machine strapped to your face every night — works, but compliance rates are notoriously low. About half of patients prescribed CPAP stop using it within the first year. That's not a failure of willpower. It's a failure of the intervention to fit into real human behavior.

Now there's clinical trial data suggesting an alternative: GLP-1 medications can reduce sleep apnea severity by more than 60%, with half of treated patients meeting the criteria for disease resolution. The trial is called SURMOUNT-OSA, and the implications for men are substantial.

SURMOUNT-OSA: What the Trial Found

SURMOUNT-OSA was a two-study phase 3 trial published in the New England Journal of Medicine in June 2024. It enrolled adults with moderate-to-severe obstructive sleep apnea (defined as 15 or more breathing interruptions per hour) and obesity (BMI ≥ 30).

Study 1 enrolled patients who were not using CPAP at baseline — people who either couldn't tolerate it or chose not to use it. Study 2 enrolled patients who were already on CPAP and planned to continue, but underwent a washout period for assessment. Both studies randomized patients to tirzepatide (10 or 15 mg) or placebo for 52 weeks.

In plain terms: tirzepatide achieved all primary and key secondary endpoints in both studies. It didn't just reduce the severity of sleep apnea — it eliminated it entirely for roughly half of treated patients, based on predetermined AHI and Epworth Sleepiness Scale thresholds at which CPAP may not be recommended.

Why This Matters More for Men

Sleep apnea is a male-dominant condition. The anatomical reasons are well-established: men tend to accumulate fat in the neck and upper airway more than women, men have longer pharyngeal airways that are more prone to collapse, and testosterone itself may promote upper airway fat deposition while reducing the protective effects of progesterone on airway muscle tone.

The consequences are disproportionate too. Untreated OSA in men is linked to hypertension, atrial fibrillation, stroke, type 2 diabetes, erectile dysfunction, depression, and motor vehicle accidents from daytime sleepiness. It's not just about snoring — it's a systemic cardiovascular and metabolic stressor that operates every night for 6-8 hours.

The CPAP Problem

CPAP is effective when used consistently. The issue is that "consistently" means every night, all night, for life. Long-term adherence data is sobering. Studies show compliance rates between 30-60% at the 1-year mark, depending on how compliance is defined. Many men try it, hate it, and stop — then continue living with untreated sleep apnea because the alternative seems worse than the disease.

This is exactly the population SURMOUNT-OSA Study 1 targeted: people with moderate-to-severe OSA who were not using PAP therapy. These patients had no treatment at baseline. Adding tirzepatide gave them a 62.8% reduction in breathing interruptions without strapping anything to their face.

Beyond Breathing: The Cardiometabolic Cascade

A January 2026 secondary analysis published in Nature Medicine examined the cardiometabolic outcomes from SURMOUNT-OSA in detail. Tirzepatide treatment improved insulin resistance (HOMA-IR), triglycerides, high-sensitivity C-reactive protein, and blood pressure — beyond what weight loss alone would predict.

The mediation analysis found that some improvements were attributable to reduction in OSA metrics (AHI, hypoxic burden) independent of weight loss. In other words, fixing the sleep apnea itself contributed to cardiometabolic improvement above and beyond the weight loss effect. This creates a positive feedback loop: lose weight → breathe better at night → reduce inflammation → improve metabolic markers → lose more weight.

What About Semaglutide?

SURMOUNT-OSA tested tirzepatide specifically. There is no equivalent large-scale RCT of semaglutide for OSA. However, the mechanism — weight loss reducing upper airway fat deposition — is shared across GLP-1 agonists. Smaller studies and clinical experience suggest semaglutide also improves OSA, but the magnitude of AHI reduction is likely proportional to the degree of weight loss, which SURMOUNT-5 showed is greater with tirzepatide.

Until a head-to-head sleep apnea trial comparing the two drugs is conducted, the strongest evidence for OSA treatment sits with tirzepatide.

Patient-Reported Outcomes: How It Felt

Beyond the clinical numbers, the patient-reported outcomes from SURMOUNT-OSA tell a compelling story. Published in Sleep in August 2025, the analysis showed tirzepatide-treated patients reported significantly better scores on sleep-related impairment, sleep disturbance, daytime sleepiness, functional outcomes, and overall quality of life compared to placebo.

For men who've been living with years of fragmented sleep, chronic fatigue, and the relationship strain that comes from severe snoring, these subjective improvements are arguably as important as the AHI numbers.

Practical Takeaways

If You Suspect You Have Sleep Apnea

Get a sleep study. Home sleep testing is now widely available and can be done without visiting a lab. Key warning signs: loud snoring, witnessed breathing pauses, waking up gasping, persistent daytime sleepiness, morning headaches, and difficulty concentrating. Your telehealth GLP-1 provider may be able to order a home sleep test or refer you to a sleep specialist.

If You're Already Diagnosed

If you're on CPAP and tolerating it, don't stop. SURMOUNT-OSA Study 2 showed benefits even for patients already on PAP therapy — the two approaches complement each other. If you've tried CPAP and abandoned it, GLP-1 therapy represents a realistic alternative for reducing OSA severity, potentially to the point where PAP is no longer clinically recommended.

Track the Right Metrics

Ask your provider to monitor neck circumference alongside weight. Neck circumference above 17 inches in men is a strong predictor of OSA severity. As you lose weight on a GLP-1, this measurement should decrease — and with it, your airway obstruction risk.

"The SURMOUNT-OSA results represent a breakthrough in the history of treatment of obesity and sleep apnea." — Dr. Louis J. Aronne, Weill Cornell Medicine

The Bottom Line

Sleep apnea is one of the most underdiagnosed and undertreated conditions in men. The SURMOUNT-OSA trial shows that GLP-1 medications — tirzepatide specifically — can reduce sleep apnea severity by more than 60% and potentially eliminate the condition entirely in about half of treated patients. For men who can't tolerate CPAP, this is the most significant development in sleep apnea treatment in decades.

If you're considering a GLP-1 medication for weight loss and you snore, the sleep apnea data should be part of the conversation with your provider. You might be treating two conditions with one drug.